Theravance Biopharma, Inc. (NASDAQ:TBPH) – Investment analysts at Leerink Swann raised their FY2017 earnings estimates for Theravance Biopharma in a research report issued on Wednesday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will earn ($4.95) per share for the year, up from their prior forecast of ($5.10). Leerink Swann also issued estimates for Theravance Biopharma’s Q4 2017 earnings at ($1.16) EPS, FY2018 earnings at ($4.75) EPS, FY2019 earnings at ($4.52) EPS, FY2020 earnings at ($3.78) EPS and FY2021 earnings at ($1.76) EPS.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, August 16th. Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. BidaskClub lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Finally, ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, September 13th. Four analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $41.86.

ILLEGAL ACTIVITY NOTICE: “Theravance Biopharma, Inc. Forecasted to Earn FY2017 Earnings of ($4.95) Per Share (TBPH)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/10/theravance-biopharma-inc-forecasted-to-earn-fy2017-earnings-of-4-95-per-share-tbph.html.

Theravance Biopharma (NASDAQ TBPH) traded up $0.79 during midday trading on Friday, reaching $28.60. The company’s stock had a trading volume of 47,234 shares, compared to its average volume of 238,488. Theravance Biopharma has a 52-week low of $23.15 and a 52-week high of $43.44. The company has a debt-to-equity ratio of 0.93, a current ratio of 6.74 and a quick ratio of 6.53.

A number of large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its position in Theravance Biopharma by 32.0% during the 3rd quarter. Wells Fargo & Company MN now owns 117,079 shares of the biopharmaceutical company’s stock worth $4,009,000 after purchasing an additional 28,391 shares during the last quarter. Legal & General Group Plc grew its position in Theravance Biopharma by 15.7% during the 3rd quarter. Legal & General Group Plc now owns 18,840 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 2,551 shares during the last quarter. American International Group Inc. grew its position in Theravance Biopharma by 8.1% during the 3rd quarter. American International Group Inc. now owns 28,000 shares of the biopharmaceutical company’s stock worth $959,000 after purchasing an additional 2,094 shares during the last quarter. SG Americas Securities LLC grew its position in Theravance Biopharma by 52.8% during the 3rd quarter. SG Americas Securities LLC now owns 9,061 shares of the biopharmaceutical company’s stock worth $310,000 after purchasing an additional 3,130 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Theravance Biopharma by 1.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 210,331 shares of the biopharmaceutical company’s stock worth $7,202,000 after purchasing an additional 2,624 shares during the last quarter. 84.54% of the stock is currently owned by institutional investors.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total transaction of $451,395.90. Following the sale, the executive vice president now owns 134,327 shares of the company’s stock, valued at approximately $4,133,241.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Frank Pasqualone bought 4,000 shares of the company’s stock in a transaction on Monday, August 21st. The shares were bought at an average cost of $26.34 per share, for a total transaction of $105,360.00. Following the transaction, the senior vice president now owns 213,180 shares in the company, valued at approximately $5,615,161.20. The disclosure for this purchase can be found here. Insiders own 6.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.